UY35785A - Derivados de piperazina sustituidos como moduladores del transportador de la glicina-1 (glyt1) - Google Patents

Derivados de piperazina sustituidos como moduladores del transportador de la glicina-1 (glyt1)

Info

Publication number
UY35785A
UY35785A UY0001035785A UY35785A UY35785A UY 35785 A UY35785 A UY 35785A UY 0001035785 A UY0001035785 A UY 0001035785A UY 35785 A UY35785 A UY 35785A UY 35785 A UY35785 A UY 35785A
Authority
UY
Uruguay
Prior art keywords
glyt1
piperazine derivatives
glicine
modulators
conveyor
Prior art date
Application number
UY0001035785A
Other languages
English (en)
Inventor
Lessel Uta
Rosenbrock Holger
Schmid Bernhard
Giovannini Riccardo
Hoenke Christoph
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY35785A publication Critical patent/UY35785A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Las presentes invenciones se refieren a derivados sustituidos de piperazina de la Fórmula general (I) y a la fabricación de dichos compuestos, las composiciones farmacéuticas quecomprenden un compuesto de acuerdo con la Fórmula general (I), y el uso de dichos compuestos para el tratamiento de diversas condiciones médicas relacionadas con el transportador de glicina-1 (GlyT1).
UY0001035785A 2013-10-16 2014-10-16 Derivados de piperazina sustituidos como moduladores del transportador de la glicina-1 (glyt1) UY35785A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13188904 2013-10-16

Publications (1)

Publication Number Publication Date
UY35785A true UY35785A (es) 2015-04-30

Family

ID=49354583

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035785A UY35785A (es) 2013-10-16 2014-10-16 Derivados de piperazina sustituidos como moduladores del transportador de la glicina-1 (glyt1)

Country Status (21)

Country Link
US (1) US9233953B2 (es)
EP (1) EP3057963B1 (es)
JP (1) JP6483105B2 (es)
KR (1) KR102281284B1 (es)
CN (1) CN105636961B (es)
AR (1) AR098037A1 (es)
AU (1) AU2014336258B2 (es)
BR (1) BR112016008062B1 (es)
CA (1) CA2926754C (es)
CL (1) CL2016000884A1 (es)
DK (1) DK3057963T3 (es)
EA (1) EA029313B1 (es)
ES (1) ES2745555T3 (es)
HU (1) HUE047044T2 (es)
IL (1) IL244693B (es)
MX (1) MX370006B (es)
PH (1) PH12016500577A1 (es)
PL (1) PL3057963T3 (es)
TW (1) TW201609716A (es)
UY (1) UY35785A (es)
WO (1) WO2015055698A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106854189A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种哌嗪化合物的合成方法
CN107778257A (zh) * 2016-08-29 2018-03-09 湖南华腾制药有限公司 一种哌嗪衍生物的合成方法
CN106977463A (zh) * 2017-05-31 2017-07-25 湖南华腾制药有限公司 一种联苯取代哌嗪衍生物的合成方法
CN107417679A (zh) * 2017-08-04 2017-12-01 河南农业大学 1,3‑唑类取代吡嗪类化合物的制备方法
JP2023509792A (ja) 2020-01-09 2023-03-09 ディスク・メディシン・インコーポレイテッド グリシン輸送阻害剤を用いて骨髄性プロトポルフィリン症、ｘ連鎖プロトポルフィリン症または先天性赤血球生成性ポルフィリン症を処置する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0224084D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
GB0505085D0 (en) * 2005-03-11 2005-04-20 Glaxo Group Ltd Compounds
WO2006113704A2 (en) 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
CN102574857B (zh) 2009-07-08 2015-06-10 利奥制药有限公司 作为jak受体和蛋白酪氨酸激酶抑制剂的杂环化合物

Also Published As

Publication number Publication date
KR20160062187A (ko) 2016-06-01
BR112016008062B1 (pt) 2022-11-16
PH12016500577B1 (en) 2016-06-20
US20150105397A1 (en) 2015-04-16
WO2015055698A1 (en) 2015-04-23
JP2016533368A (ja) 2016-10-27
EA029313B1 (ru) 2018-03-30
BR112016008062A2 (es) 2017-08-01
CA2926754C (en) 2021-09-14
NZ718251A (en) 2021-02-26
US9233953B2 (en) 2016-01-12
IL244693A0 (en) 2016-04-21
EP3057963B1 (en) 2019-06-19
TW201609716A (zh) 2016-03-16
MX2016004847A (es) 2016-07-19
KR102281284B1 (ko) 2021-07-23
PL3057963T3 (pl) 2019-12-31
EA201600323A1 (ru) 2016-10-31
MX370006B (es) 2019-11-28
AU2014336258B2 (en) 2018-07-12
PH12016500577A1 (en) 2016-06-20
HUE047044T2 (hu) 2020-04-28
CA2926754A1 (en) 2015-04-23
CN105636961B (zh) 2019-11-05
CL2016000884A1 (es) 2016-12-30
AR098037A1 (es) 2016-04-27
ES2745555T3 (es) 2020-03-02
IL244693B (en) 2019-08-29
DK3057963T3 (da) 2019-09-16
JP6483105B2 (ja) 2019-03-13
CN105636961A (zh) 2016-06-01
EP3057963A1 (en) 2016-08-24
AU2014336258A1 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
DOP2017000304A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
EA201401292A2 (ru) Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их
DOP2015000157A (es) Lactamas fusionadas de arilo y heteroarilo
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
CR20170590A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
CR20150447A (es) Nuevos derivados de pirazol
CO6781507A2 (es) Novedosos derivados heterociclicos
CU20140081A7 (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY36702A (es) Piridinas sustituidas y métodos de uso
CU20170085A7 (es) Derivados de imidazolidindiona para el tratamiento de la osteoartritis
CR20150440A (es) Nuevos derivados de piridina
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
CR20130569A (es) Análogos del ácido epoxieicosatrienoicos y métodos de toma y uso del mismo
EA201500931A1 (ru) Производные пиридин-4-ила
CR20150511A (es) Nuevos derivados de purina
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
CR20160016A (es) Pirazolpiridinas sustituidas
BR112017012005A2 (pt) compostos orgânicos
UY35785A (es) Derivados de piperazina sustituidos como moduladores del transportador de la glicina-1 (glyt1)